M PREMKUMAR
@docMPK
Followers
1K
Following
1K
Media
131
Statuses
805
Stranger in a Strange Land
Chandigarh, India
Joined May 2021
📴📰CRRT in Acute Liver Failure - Rationale,Evidence,Practice -Beyond Kidneys -Real world issues With @AnandVKulkarni2
@ajay_duseja @docMPK @MaiwallRakhi @drnipunverma @drshalimar @RobertFontanaMD @ebtapper @RohitMehtaniDM @JasmohanBajaj 👇🏽Check out now
jcehepatology.com
Acute liver failure (ALF) is a life-threatening condition hallmarked by an acute onset of liver dysfunction, coagulopathy, and encephalopathy in individuals without pre-existing liver disease....
3
14
31
From today's edition of @the_hindu 'across all sites the chimpanzees consumed 14 gm of ethanol daily' however this is imbibed slowly... Humans can take a cue.
2
1
4
In cirrhosis, mortality in the ICU was driven by organ failure, not infection — showing the need to act earlier. Colonization didn’t predict infection, but when infection occurred, it often matched the colonizing strain.
wjgnet.com
Clinical impact of multidrug-resistant organisms in liver cirrhosis: A retrospective cohort study in the intensive care setting
5
8
19
Advance Hepatology with JCEH 📊 Impact Factor: 3.2 📈 CiteScore: 5.1 ⏱️ Editorial decision: ~4.9 days ⚡ Online publication: ~4.9 days post-acceptance 📢 Now inviting high-impact liver research. 📝 Submit today 👇🏽 https://t.co/2E4qyL96mQ
@AnandVKulkarni2 @docMPK @ajay_duseja
1
11
27
@salvatore_piano @RohitMehtaniDM @JCEH_Hepatology @stevenbollipo @juanpabloarab Do read the companion review on POCUS guided Fluid resuscitation in Cirrhosis Semin Liver Dis 2025; 45(02): 252-268 DOI: 10.1055/a-2515-2783 @hepocus @drkeithsiau Current Concepts in Fluid Resuscitation and Vasopressor Use in Cirrhosis - PubMed
pubmed.ncbi.nlm.nih.gov
Critically ill patients with cirrhosis and liver failure do not uncommonly have hypotension due to multifactorial reasons, which include a hyperdynamic state with increased cardiac index (CI), low...
0
0
3
Following POCUS-guided volume management, 231(62%) had pre-renal AKI; 61(16.4%) hepatorenal syndrome(HRS-AKI); 25(6.7%) HRS-AKD; 32(8.6%) HRS-CKD, while 23(6.2%) had a multifactorial etiology. @salvatore_piano @RohitMehtaniDM @JCEH_Hepatology @stevenbollipo @juanpabloarab
2
2
5
‘Point-of-Care Ultrasound (POCUS) guided volume management... : Hepatology https://t.co/c63bvQA9VZ. patients with AKI [84.7% men, aged 50.3±12 years, MELD-Na 23.9±5.1]; 296(79.6%), 42(11.3%), and 34(9.1%) were classified as hypovolemic, euvolemic, and hypervolemic at Timezero.
journals.lww.com
and survival, in cirrhosis and AKI between January 2023 and November 2024. Exclusions were patients with structural cardiac disease, portopulmonary hypertension, acute variceal bleeding, and septic...
1
13
30
Impact of Cirrhotic cardiomyopathy on outcomes in AKI 🚦Fluid resuscitation and use of vasopressors like terlipressin can be guided by POCUS. 🎯 CCM variables like mitral tissue Doppler offer AKI trajectory prediction Close association of CCM either HRS AKI @HEP_Journal
0
2
10
‘Point-of-Care Ultrasound (POCUS) guided volume management... : Hepatology https://t.co/c63bvQA9VZ Now online. #livertwitter @ajay_duseja @drnipunverma @AnandVKulkarni2 @hepocus @Florent_Artru @manhalizzy @ebtapper POCUS to classify volume status in Cirrhosis & AKI Trajectory
5
26
62
🙌🏽 Learning experience knowing and constructing this 🙏🏽🙏🏽 Prof Raj Reddy @AnandVKulkarni2 @AGA_GHAdvances
📣 Gene therapy is making rapid strides for multiple indications. However, hepatotoxicity is a concern. Careful risk factor assessment and multidisciplinary management are key to improving outcomes. 👨⚕️ @RoyAHep @AnandVKulkarni2 🔗 https://t.co/VJv39IrVco
0
2
8
📜 ⚠️Check out @JCEH_Hepatology Summary of data on 🔸Biopsy in ALF 🔸Dynamic scores in current era 🔸PLEX, CRRT 🔸ONSD , TCD 🔸🇮🇳 Concerns 🙌🏽 @docMPK
@ajay_duseja @AnandVKulkarni2
@MaiwallRakhi @RohitMehtaniDM @INASL_Liver @RobertFontanaMD
@drshalimar
https://t.co/0o30K5N1Du
2
14
22
Preparando últimos detalles del workshop de #POCUS en el Congreso de Lima, Perú de @alehlatam. Últimos lugares. Los esperamos. Con el apoyo de @GusiPocus. Save the date 01 octubre 2025 !! @docMPK
0
1
5
In ~3,000 individuals at risk of SLD: 🔍 39% of MASLD (by self-report) could be reclassified as MetALD (>20 ng/mL) or ALD (>200 ng/mL) using PEth ⨻ Triangulating with self-report, AUDIT-C and PEth refines SLD subclassification ✅ ⚖️ 40% of SLD cases: PEth seems redundant
New research - Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study https://t.co/cqyMwtuQUI
#LiverTwitter #MedTwitter @AleksanderKrag
2
15
41
Mortality is still 12% at 6 months… not a benign condition at all #LiverX
📑 Moderate alcohol-associated hepatitis: A real-world multicenter study‼️ mAH has ⬆️ 💀 rates, driven by age, organ failure, infections, and variceal 🩸 . Current risk scores perform poorly in mAH https://t.co/oi9ZNE20oY
0
4
20
Be there or be 🟦
All about Liver in 2025 only @ AIG Liver Conclave . Signature speaker series by @ArunJSanyalVCU Prof Angeli Prof Kamath and Prof Reddy AIG liver conclave nearing 1k registrations. @RoyAHep @ebtapper @sonalasthana @MajaThiele @JasmohanBajaj @VCU_Liver @JunedKh47457225
0
1
3
@BavenoCoop @ebtapper @docMPK @Dr_Ampuero @DrCynthiaLevy @CholestasisDoc @clbowlus @macarlotal @DrAliyaMD @aldomontanoloza @kremer_andreas Predictors of RECOMPENSATION: ✅MELD < 15 ✅Viral-related cirrhosis 🤔Challenge the traditional "irreversible" view of Decompensated cirrhosis Full study 👉 https://t.co/JZSLHeTt4s
#LiverX @AGA_CGH
0
4
13
💥A simple & reliable #POCUS method to assess #sarcopenia in #cirrhosis - now in @JHEP_Reports ✅ Accurate vs CT ⚡️ Fast (1-min test) 💵 Low-cost 🎯 Linked to clinical outcomes 🏥 https://t.co/Q7Tmc77IPu
@hepocus @docMPK @docberza @CirrhosisCareAB @ebtapper @EASLnews
4
23
56
